American Trust Purchases Shares of 3,487 Gilead Sciences, Inc. (NASDAQ:GILD)

Posted by Defense World Staff on Sep 16th, 2023

Gilead Sciences logo American Trust purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,487 shares of the biopharmaceutical company’s stock, valued at approximately $289,000.

Other large investors have also recently bought and sold shares of the company. ST Germain D J Co. Inc. grew its position in Gilead Sciences by 15.2% in the fourth quarter. ST Germain D J Co. Inc. now owns 4,246 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 560 shares during the period. Heritage Wealth Management LLC grew its position in Gilead Sciences by 54.6% in the fourth quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 130 shares during the period. SJS Investment Consulting Inc. grew its holdings in shares of Gilead Sciences by 187.9% during the first quarter. SJS Investment Consulting Inc. now owns 403 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 263 shares during the last quarter. Sanctuary Wealth Management L.L.C. bought a new stake in shares of Gilead Sciences during the fourth quarter worth $33,000. Finally, Venturi Wealth Management LLC bought a new stake in shares of Gilead Sciences during the first quarter worth $36,000. 82.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 1,501 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Gilead Sciences news, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,399,308.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the chief financial officer now owns 107,587 shares of the company’s stock, valued at $8,606,960. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on GILD shares. StockNews.com started coverage on Gilead Sciences in a report on Thursday, August 17th. They set a “strong-buy” rating on the stock. Piper Sandler decreased their target price on Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, July 24th. Barclays decreased their target price on Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, July 24th. Cantor Fitzgerald cut their price target on Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 19th. Finally, Royal Bank of Canada upped their price target on Gilead Sciences from $83.00 to $84.00 and gave the company a “sector perform” rating in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.05.

View Our Latest Stock Analysis on GILD

Gilead Sciences Trading Down 2.2 %

NASDAQ GILD opened at $75.67 on Friday. The firm has a market cap of $94.29 billion, a P/E ratio of 17.40, a P/E/G ratio of 0.83 and a beta of 0.37. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.02 and a quick ratio of 0.91. The stock’s 50-day moving average is $77.26 and its 200-day moving average is $78.84. Gilead Sciences, Inc. has a one year low of $61.44 and a one year high of $89.74.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.30). The firm had revenue of $6.60 billion for the quarter, compared to the consensus estimate of $6.45 billion. Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.58 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.64 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.96%. Gilead Sciences’s payout ratio is presently 68.97%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.